Notice of References Cited
`
`Application/Control No.
`
`13/750,352
`
`Examiner
`
`Aarti Bhatia Berdichevsky
`
`U.S. PATENT DOCUMENTS
`
`Name
`
`Date
`MM-YYYY
`
`07-2000
`
`Sudo etal.
`
`08-2006
`
`Wiegand et al.
`
`11-2006
`
`Lubrecht, Thea E.
`
`08-2007
`
`Shams, Naveed
`
`12-2007
`
`Wiegand et al.
`
`12-2008
`
`Delmotte et al.
`
`11-2011
`
`Hioki et al.
`
`Applicant(s)/Patent Under
`Reexamination
`SIGG ET AL.
`
`Art Unit
`
`3763
`
`I Page 1 of 1
`
`Classification
`
`604/230
`
`514/012
`
`604/230
`
`424/145.1
`
`424/134.1
`
`604/230
`
`604/187
`
`Document Number
`Country Code-Number-Kind Code
`
`A US-6,090,081 A
`
`F
`
`*
`*
`*
`B US-2006/0172944 A1
`* C US-7,141,042 B2
`* D US-2007/0190058 A1
`*
`E US-7,303,748 B2
`*
`US-2008/0312607 A 1
`*
`
`US-2011/0276005 A1
`
`G
`H US-
`US-
`
`I
`
`US-
`
`J
`K US-
`US-
`
`L
`M US-
`
`*
`
`Document Number
`Country Code-Number-Kind Code
`
`Date
`MM-YYYY
`
`Country
`
`Name
`
`Classification
`
`FOREIGN PATENT DOCUMENTS
`
`NON-PATENT DOCUMENTS
`
`Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
`
`*
`
`N
`
`0
`
`p
`
`Q
`
`R
`s
`T
`
`u
`
`V
`
`w
`
`X
`
`•A copy of this reference 1s not being furnished with this Office action. (See MPEP § 707.0S(a).)
`Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.
`
`U.S. Patent and Trademark Office
`PTO-892 (Rev. 01-2001)
`
`Notice of References Cited
`
`Part of Paper No. 20140507
`
`Novartis Exhibit 2055.001
`Regeneron v. Novartis, IPR2020-01317
`
`

`

`Approved for use lhrou11h 0713112012. 0MB 0651-0031
`Doc description: lnfo11nation Disclosure Statement (IDS) Filed
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no pe1SOns are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`13750352
`
`Filing Date
`2013-01-25
`First Named Inventor I Juergen Sigg
`Art Unit
`
`Examiner Name
`
`I
`Attorney Docket Number
`
`PAT055157-US-NP
`
`Examiner Cite
`No
`Initial*
`
`Patent Number
`
`Kind
`Cocte1
`
`Issue Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`U.S.PATENTS
`
`Remove
`
`1
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`Add
`Remove
`
`Examiner
`Initial*
`
`Cite No
`
`Publication
`Number
`
`Kind Publication
`Cocte1 Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`1
`
`If you wish to add additional U.S. Published Application citation information please click the Add button. Add
`Remove
`FOREIGN PATENT DOCUMENTS
`
`Examiner Cite Foreign Document
`No Number3
`Initial*
`
`Country
`Code2 i
`
`Kind Publication
`Code4 Date
`
`Name of Patentee or
`Applicant of cited
`Document
`
`Pages,Columns,Lines
`where Relevant
`Passages or Relevant
`Figures Appear
`
`Ts
`
`1
`
`□
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button
`
`NON-PATENT LITERATURE DOCUMENTS
`
`Add
`
`Remove
`
`Examiner Cite
`Initials* No
`
`Include name of the author (in CAPITAL LETTERS}, title of the article (when appropriate}, title of the item
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`publisher, city and/or country where published.
`
`TS
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ABB/
`
`Novartis Exhibit 2055.002
`Regeneron v. Novartis, IPR2020-01317
`
`

`

`Receipt date: 03/28/2014
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`13750352
`
`2013-01-25
`Filing Date
`First Named Inventor I Juergen Sigg
`Art Unit
`
`13750352 - GAU: 3763
`
`Examiner Name
`
`I
`Attorney Docket Number
`
`PA 1055157-US-NP
`
`1
`
`Badkar et al., "Development of biotechnology products in pre-filled syringes: technical considerations and approaches·,
`AAPS PharmaSciTech, Vol. 12, No. 2, pp. 564-572, (June 2011)
`
`□
`
`If you wish to add additional non-patent literature document citation information please click the Add button Add
`EXAMINER SIGNATURE
`
`I Date Considered I os10112014
`Examiner Signature I /Aarti Bhatia Berdichevskv/
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
`
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO
`Standard ST.3). 3 For Japanese patent documenls, the indication of the year of the reign of the Emperor must precede the serial number of the patent document
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Slandard ST.16 if possible. 5 Applicant is to place a check mark here i
`English language translation is attached.
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ABB/
`
`Novartis Exhibit 2055.003
`Regeneron v. Novartis, IPR2020-01317
`
`

`

`Receipt date: 01/29/2013
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPUCANT
`.~ I# Mlffl)f Shetits ll!iLl!eC.SUi)')
`
`Aoolioatii:m Number
`FiijngOti.te
`FifsfNamed lriVeotot
`Artunit
`
`13/750352
`.,.Jam;arv 25 2013
`
`AttOrne\.' Oocket Number l PAT055157-US-NP
`
`US 200612'93270 A 1
`US 2011-257601A1
`us 2010/031.0309
`
`:2011-10,.20 Ftn:fine et al.
`2010,.12;.()9 Abendroth et aL
`
`·p•s,~,Une$, ~ ·
`~evar,I Passge;, (l( l'leliMonl
`fi<ilir.,.,.,,,_;,
`
`I
`
`I
`
`l
`
`2007-03"-29
`WO 2001/035621A1
`OE 10 2008 005938 A1 {equivalent 200S:Q1·$0 Arzheimittel· Qml:iH
`toUS:2010/031030'9)
`.
`ApothekerVetttr & Co,
`
`N~Wi>fP~lo,i~il(
`Apj!lcar!lol<llliod ~t,\t
`
`Pi!gii>$, <!\'l~jM; I.oles,
`~ : Rellrff.111 P~S6-;e,, or
`Reii,;a1,tf~es,~
`
`lll<:lµrie n11m.,,,; 1n .. a<Jtllof, .. c11r;iT.At.1.emRei; ti~ 111.~ ol!lic/e~ ap~rtiprialli).lih Of 111e, •t<mi1~- ~~,,j~n\ii1.~~. ~i!>ffl,
`'"1~,$11,.'). dllle>, PllO-(S), I I~~ llutt,m,,'(;>), P.lll;il!'ir/l)!',<>\!Ya>""1tltoowJW~P.~blia'l1!><!.
`Ausubel et a!,, •corterit?roto.eols. in Molecular Siology-',. 7,i;lS of Cun-ent protocol's in Mo!ec1.1l~r
`·
`ato!◊gy, edis,. ~ypptement 3i:l;{t91:17)
`
`T"
`0
`Cl
`l
`□ 1
`:
`
`□ i
`0
`
`□
`
`□
`Cl}
`
`oa.te
`Examiner
`/Aarti Bhatia Berdichevsky/
`05/07/2014
`Si natu'9
`Considenld
`~f~!NER:. lnlllal jf ref'lire@ ¢!.)1\$~. ~.~ 1J« tjtatianls i!'l <lOotormatlQl with Mf'EP 6W Pta.w~ I~ through Clt,allOn lf not,ifl 0011rortJ~n®
`®'Ci ri<ltr;,naotdema, . lil@d& i;:op)I of this ~ \~Ill ~ i:ieit.tcomm1inic;ati~ 10 ~fi!iCant 1 1.pprK;1nh unique c1tation ~~lion n1.1mber(®lttm11I)<'
`~1!<ind.CQ/le$.<if V$PTO Pi!l/mt.001;1Jm1W!$lil.WWW;u1$p!.Q.~ otMPl:P l!Q1 04. ·1.ion~r Office ~t/s$1,1ed lhe.~nt; by the ~le~r'i;.cdrt.(WlPO
`~i.n#ar~ $1:.;¼}, •. for Ja~nes.e J)l\l.ttrll d~i;m!llllB, th!! in(jicatji:,n of .. !tie .~fllir of the reign .of the,. Emperqr m;is:t pre<»cle the se!')al number of 111e petimt
`dQ(llJll\E!nl. .~ Kllld'of ~n t by .tt\e appttipriate.symbb!J tts til(I~ oo tlla ~n t i.,nd&r WIPO S!iiildlli:d .• sr: 1& .if !)¢$$Ible. ··~ Aj)plfcant 1s II:! place
`a ~de mat'~ hereilfi~ll$h tansu~ T~o!'llaijon is~ ' .
`Thi$ ool~iioo QI' il'.lformation is ieq11lred by 31 CFR 1. ~-, .and. UI~ Th!I. ji\formiillon l:11.r~irled to ®ialn or retain A tleli!iflt by the putlffc will;:!, i.~ to file
`tand bY the tJSPTO to pr~) an application, .ConfidentiillitY ti; govern~ lW ~iHJ.S.C, ·122 am:/ J1' CPR 1. tit ThiJ ¢tiltectlon ill esllma!$d 10 f;.jk~ 2
`hQU~ I!> l:011'fll• · i!\Cfil!lmg ~ ; prepanng, • ,md sul:lmittlng. tne .e.(ffl)~elett app!illatlOn .form .tctl1e QSPTO. Ti~ <>,1ll 11art ®peroltlg t.iPQl1 the·
`ir\i'Jivldu:al case . . MJ ~ll!lill!inlli on tile al'l)l.iunl of Im yllt! fDq!Jll'e ta !;:OF11pl~ lhis form and/01' s~ges~ fGr rl!dooing this bu~n, shoulq be sef!j to ~
`Ch~ lrt!orrtlaliot1.0ff!Q&!', U;.$. Patent and Trademark Offiile, .l";O . .l}f,,'°14~0, Al~~; VA ;z2313-1¥,0. DO NOT SSiilO FEES OR COMPi.;.ETEO
`F'ORMS TO 'i'HISAOOR£S$ .. &ENO . .TO: Co~/$$1citler~r P.llt~, P,9; Bmt-i-4$0, A.l~llttdl'ltl, VA 22313-14$Q:.
`If you tteeaaS&s~.ifl wn'iPleNl'Jflflle fPfm.• ~ail 1·800'.f'TD'91!.19 (1•81»7'86-91~) iln(} $ii/fl{,/ <;1p/itjn f
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ABB/
`
`Novartis Exhibit 2055.004
`Regeneron v. Novartis, IPR2020-01317
`
`

`

`Receipt date: 03/19/2013
`
`App19,""1.fur 11$.,J.r~~~~~t 3763
`
`lJ.S. Pateni ,sr-,li "fn1demi!!11 Offi<:f,; iJ S . .oE'PAl'!TMENT Of COMl\lE'RGE
`ti•;,, ~i,,,r in!onn.,::i;,n m•~ itcu,,!>)ins,a VIS!ki CMS "~t•o! ncrnber,
`
`I
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPUCANT
`(~ M·ma,w ~.as ne~~}
`! .
`·--·----
`
`············ ... " ...... ..
`
`Stteet ...... l ........ ..
`•smsrnsm::s~~
`
`! of i..ki=·~,s~
`u.s~·?ATENT OOeuuf:RTS
`............ ~-·-·······----
`. ................................. - -~~ , ............... ~ ............................................................ ~-----·
`1------,---"-,~-..................................... -................................... _
`... ""' -....................
`! >.<c.:' r-···
`._,m.-.... .... " ... ._m, j Pubt;r<~U~1 llam
`~ e:~~
`~oo,a· ~ Pater,m ❖f
`~
`•1 ~~. Coki. mna.. Unm: .. \J\ll)ESt8
`E-x>.i!'rn.~~r
`f.xlt;:;rnent ·Numb$1
`.~lro"'rt oi C:ired 00¢,,.mrt
`l
`Rol,,;,~m J";;a..'<!l~•• (Ir Re!<Nw1l
`i,lM•PO-•YY'f'f
`Nmn!>ar-J<in,1 Cod<'',,;,.~••
`l!li!!al;'
`---1---------
`--·-~
`l-------1
`---·--
`l
`F!Jm~.i2,._e.,;s,-;.... __ --1
`.... L ....... l US•
`.................................. ···········l ........ ·---------1-----· .. ·----·-------------·-"'·······--·------------··1 ..... ___ ...,. ___ _
`l
`................................ -----------,1----~--------------------
`!
`! US- ----------
`--------·--------i,L ..................... -- ,---~-----•-·---t_'._· .. ·
`........... , ......... !--~"_,,. -
`.._,_.._.....,_.~.._.,_...,._._, ~ ........... u.._._._._._., - - - - - - - -~ ................ --~1----............ ,"'"'"n,, ............ • ...... u ..... c,.-.. .. -,.-,.,.-a,-,,.,,.. .. , } .. -.,,, ____ __ ._.,_.._,.._.._.._ . .
`'
`! US-
`,
`! US·
`'t
`j
`______ ...., ________ _
`I us-
`----------------................. ·-··-----·--------
`i
`l ........ l ... u;········-·······• --------------1_·----·-----~
`-· 1 - - - - - - - - - -
`t .....
`1 ............................. ~ ~.--•" +·1.-:...-.:· ........ """""'-"""
`
`. . . . . . . . . . . . ~•n•h
`
`--,ann'-'-••h
`
`~,,'•uuuu ......... _.._._.. .. ,.,.........,.,.,.i............
`
`I
`..................... ,.............., ..... .........,. .... ________ ,~ , .... ,u ............ ,.,.,,.,"
`
`WS·
`
`1
`
`1
`
`............................ -.... -~ .......................................... _...,. _______ ............................................. , ...... "'_ ...... ·: __ _
`
`1·1 .. 0·1-2012 l \/VONG, VERNON, G.
`j
`t 0
`½'O 20121149040 A2
`............. !,.:;:.,:; .. ''>!~ff• i REGENERON
`--·-----·t·····1wo"ioo-7-f1-49334 h\2
`""""t·---·-----i -Cl ....
`I PHARMACEUT!CALS,!NC
`!
`'
`i
`-••••••• .................. ..-..... ,....L._,.
`+~•·"-•• .... ._ . ._ ...... ••• ~ •••••--------
`!-----!---,•••• §-. ...... non ____________ ...._,
`1 D
`! WO 2012/13.4528 A1
`i 10 .. Q,t .. ~)1;1 ! OCUJECT, LL:C
`!
`·--·1-------------------·t .......................................... _,•---------------...................................... ....,.._ ..... t
`I
`0
`\
`l ......... +·----·-------~----+· -----+--~---
`•
`1
`!
`
`I
`
`rm! I ---~------= 1 =1 ==·-· _· - -·-i.,,L_ ...... _ ... ·----•□----1
`
`:-
`
`............................................. ....,..,.,.. ......................................... ______ ,___ ............ ____________ .,... ___ ._ .............. , ............................... .
`i ···········••··•·····t, .. ,
`[1~::: 'T_, /Aarti Bh~~~-~:·;~;~::~~~--"'""-"-""_, ___ ,_,,,,,,,, :;:::: .. 'T"'"o5/07/2014-""-"'"'"''"-7
`---~~ .. --,------·--------------------------~-"--,--------1~ <
`""'----~---------,---="""""'-'-'-'-'-'-"'-"-........ !
`'
`'EX.<\M!NER: lliffiai i! ref!,m,mCll !J.'Jrn!lde1<'1l. Whetrn!t or not cits!k~1 is iN cootc,,·manoo wiih MPF.J> 609, Qra,i a IIN!> !hroui;r,i citaliOl'I II N(;! In oooformarl!'8
`' App11,.-am·~ ,,,;ir.,in diatlon dssignstion numb,sr (optlona!). 2
`ar.d no! t.o,1sid<!\r~. !ncitide C<lP\I' cf .!his form w:tt, !tl<i ne.i<t. CQ!lm1c'l1icafu:>n !o ai:>!>f}:tar;l.
`See. Kim! c:0s.~s of USPTOPate:1; pocum;mts al w,iw.Ullplc;,gw M MPEl' il>(>1 9"! • ~:n10r Df.:c.i !hst l.'!SUM the document, by the m,-..i,;,lter cml•o. (WIPO
`St.irn:iaro sr.i:,. ~ i'"or Japanes'I) pa-<ent (lc,cumenm. me inclicatlon of !he y,1ar .Qf. !t,t, ,eign o!' lh<> fanper-.x m,M p,-eoode lhe.e9ri,;ai mimter c;f the p1$tent
`doci,ment. ~ 1<1:,(l ti! <'l!)rA<mimt l:ly tl'!e app11)j)1iaie syr,ib®J. m; s1<11cal&d or, t!w (l('.<:umari! w,der \1\/IPO Stand~rd ST .1 a i! possible. 8 App!lc.iot is to piac,.3
`a cr.ecil rnaik tis:ie.if Englir.;h larigu:ige Transiaoon ;i, attw:,hed.
`This ool~tion of infurmasiion ii; cequi~d by ~7 C-FR i.97 and 1.9!l. The info,mafon is required to Qb\ain m· r<itsln a benefit bytheoubilc whkh re; j;J m,.,
`(and by tt10.USf>TO ti, .-,rr«u} sn applic:.i!!on. Cmiff~1~11llty io, governi!<1 bY 35 lJ.S,C .. 122 aml '.!it CPR 1.14. This co!lootic,o is <m!irri!,Wl 19 take 2
`r.-:•.Jm to q:,,-npieite, im::ludlng g.atl'lernig, prapming .. a~d submitti~ t'le ,::t;mp~ted appl•cstiar, form tr, tt-.a USP,Q. Time wi~ v~t depe:"lding 1.;pm1 !he
`indi-.idua! ~e .. Any '""mmllf'~S on the amouh! vf timi; 100.t<>s.•.iiffl .tr, cc.imp!ete tills rorm ar:(lfor 11ug11eslions for reducing this b,i:"defl, sh.."1Uid be ~ni to .the
`Chief l:"l!ormalion Officer, U.S. Palej":t araj Traoomaii< Office, p.o, !k>J,: 1450, Alexi1i1<.Via, VA 2Z~.1~A46(l. DO NOT SEND FEES DR c:OfvlPLETED
`FORMS 'f'OiHlS ADDRESS s~o TO: commlsslon.w for f'at&ntii, P.O. SOJi 1~.Alei::alltlrni, VA. 2.23t:M4ii0,
`,'fJA>l< n&<;,t assi:~t~rr,-:eJn comp/~irrg I/re !hrm, c,!r// 1-80Q-PTO-in99 (1-ilD0-7Bil,·!J199) alld.se1ecn.,pu1.m 2.
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ABB/
`
`Novartis Exhibit 2055.005
`Regeneron v. Novartis, IPR2020-01317
`
`

`

`Approved for lJ~~~~~-0:,.7 63
`Receipt date: 01/25/2013
`U.S. Patent and Trademark Offica; U.S. DEPARTMENT OF COMMERCE
`Under the Paoerwork Reduction Aa of 1995 no oersons ere reouired to res nnr1 to a collection of lnforinallon unless ft contains a valid 0MB control number.
`
`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`{Use as many sheets as necessary)
`I of I
`
`1
`
`1
`
`Sheet
`
`I
`
`Com11lete if Known
`Aoolication Number
`Not vet known
`Herewith
`Filina Date
`Sinn Juergen et al.
`First Named Inventor
`Art unit
`Examiner Name
`Attomev Docket Number PAT055157-US-NP
`
`Examiner
`lnltlals•
`
`Cite
`No.'
`
`Document Number
`Number-Kind Code'r>'._
`
`U.S. PATENT DOCUMENTS
`Name of Patentee or
`Publlcaflon Dete
`MM-DD-YYYY
`Applicant of Cited Document
`
`Pages, Columns, Unes, Where
`Relevant Passages or Relevant
`Flaures An.,...,.
`
`US-
`us-
`
`Examiner
`Initials*
`
`Cite
`No.'
`
`Examiner
`Initials•
`
`Cite
`No.'
`
`FOREIGN PATENT DOCUMENTS
`Publication Date
`Name of Patentee or
`MM-DD-YYYY
`Applicant of Cited Document
`
`Pages, Columns, Lines,
`Where Relevant Passages or
`Relevant Figures Appear
`
`Foreign Patent Document
`Counby Cods' Number" Kind Code'1'_,,
`WO2010/060748
`WO2011/135067
`
`06-03-2010 Molecular Partners AG
`11-03-2011 Molecular Partners AG
`
`NON PATENT LITERATURE DOCUMENTS
`Include name of the author (In CAPITAL LETTERS), tllle of the article (When appropriate), title of the Item (book, magazine, journal, serial, symposium,
`catalog, etc.), date, page(s), volume-Issue numbel(s), publisher, city and/or counlly where publishe<i.
`Badkar et al., Analysis of Two Commercially Available Bortezomib Products: Differences in Assay
`of Active Agent and Impurity Profile » AAPS PharmaSciTech, Vol. 12, No. 2, pp. 564-572, (June
`2011)
`
`Schoenknecht, "Requirements on pre-fillable glass suringes", AAPS National Biotechnology
`Conference 2007 -Abstract no. NBC07-000488, 2007
`
`Holash et al., "VEGF-Trap: A VEGF blocker with potent anitumor effects•, PNAS USA, Vol. 99, No.
`17, pp.11393-11398, (August 20, 2002)
`
`Riely & Miller, •vascular Endothelial Growth Factor Trap in Non-Small Cell lung Cancer", Clin
`Cancer Res, 13:4623-7s, (August 1, 2007)
`
`Li et al., "KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical
`treatment for corneal neovascularization•, Molecular Vision, 17:797-803,(March 25, 2011)
`
`Smith & Waterman,• Comparison of Biosequences•, Adv Appl. Math, 2:482-489, (1981)
`
`l"
`□
`□
`□
`,..
`
`□
`
`□
`
`□
`
`□
`
`□
`
`□
`
`□
`
`/Aarti Bhatia Berdichevsky/
`
`Examiner
`Date
`Considered
`Si nature
`05/07/2014
`*EXAMINER: Initial If reference considered, whether or not citation Is in conformance with MPEP 609. Draw a line through citation if not in conformance
`and not considered. Include copy of this form with the next communication to applicant. 1 Applicant's unique citation designation number (optional). 2
`See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO
`Standard ST.3). 4 For Japanese patent documents, th$ Indication Of the year Of the reign of the Emperor must precede the serial number of the patent
`document. 6 Kind of document by the appropriate symbola as indicated on the document under WIPO Standard ST.16 if possible. 8 Applicant Is to place
`a check mark here if English language Translation Is attached.
`This collection of information Is required by 37 CFR 1,97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file
`(and by the USPTO to process) an application. Confidentiality Is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2
`hours to complete, Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the
`indMdual case. Any comments on the amount of lime you require to complete this form and/or suggestions for reducing this burden, should be sent to the
`Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED
`FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460.
`If you need assistance in completing the form, ca/11-800-PT0-9199 {1-BOC-786-9199) and select option 2.
`
`PTO/SB/08a (07-09)
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ABB/
`
`Novartis Exhibit 2055.006
`Regeneron v. Novartis, IPR2020-01317
`
`

`

`Approved for use lhrou11h 0713112012. 0MB 0651-0031
`Doc description: lnfo11nation Disclosure Statement (IDS) Filed
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no pe1SOns are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`13750352
`
`2013-01-25
`Filing Date
`First Named Inventor I Juergen Sigg
`3767
`Art Unit
`I Unknown
`PAT055157-US-NP
`Attorney Docket Number
`
`Examiner Name
`
`Examiner Cite
`Initial*
`No
`
`Patent Number
`
`Kind
`Cocte1
`
`Issue Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`U.S.PATENTS
`
`Remove
`
`1
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`Add
`Remove
`
`Examiner
`Initial*
`
`Cite No
`
`Publication
`Number
`
`Kind Publication
`Cocte1 Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`1
`
`2
`
`3
`
`2013012918
`
`AA
`
`2013-01-10
`
`FOSTER GARY
`
`2012078224
`
`AA
`
`2012-03-29
`
`OCUJECTLLC
`
`2006172944
`
`AA
`
`2006-08-03
`
`WIEGAND STANLEY J
`
`If you wish to add additional U.S. Published Application citation information please click the Add button. Add
`Remove
`FOREIGN PATENT DOCUMENTS
`
`Examiner Cite Foreign Document
`Initial*
`No Number3
`
`Country
`Code2 i
`
`Kind Publication
`Code4 Date
`
`Name of Patentee or
`Applicant of cited
`Document
`
`Pages,Columns,Lines
`where Relevant
`Passages or Relevant
`Figures Appear
`
`Ts
`
`1
`
`2007084765
`
`WO
`
`A2
`
`2007-07-26
`
`POTENTIA
`
`□
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ABB/
`
`Novartis Exhibit 2055.007
`Regeneron v. Novartis, IPR2020-01317
`
`

`

`Receipt date: 06/04/2013
`
`Application Number
`
`13750352
`
`13750352 - GAU: 3763
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`2013-01-25
`Filing Date
`First Named Inventor I Juergen Sigg
`3767
`Art Unit
`I Unknown
`PAT055157-US-NP
`Attorney Docket Number
`
`Examiner Name
`
`2
`
`2006128564
`
`WO
`
`A1
`
`2006-12-07
`
`BAXTER INT
`
`3
`
`2006047325
`
`WO
`
`A1
`
`2006-05-04
`
`SHAMS NAVEED
`
`4
`
`201578690
`
`CN
`
`u
`
`2010-09-15
`
`JIANYOU WANG
`
`English Abstract
`
`5
`
`2371406
`
`EP
`
`2011-10-05
`
`Taisei Kako Co., LTD
`
`equivalent of
`WO2010/064667
`
`6
`
`2001-104480
`
`JP
`
`2001-04-14
`
`Daiko Seiko LTD
`
`English Abstract
`
`7
`
`2010136492
`
`WO
`
`2010-12-02
`
`Glaxo Group Limited
`
`□
`
`□
`
`□
`
`□
`
`□
`
`□
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button
`NON-PATENT LITERATURE DOCUMENTS
`
`Add
`
`Remove
`
`Examiner Cite
`Initials" No
`
`Include name of the author (in CAPITAL LETTERS}, title of the article (when appropriate}, title of the item
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`publisher, city and/or country where published.
`
`rs
`
`1
`
`□
`
`If you wish to add additional non-patent literature document citation information please click the Add button Add
`EXAMINER SIGNATURE
`
`I Date Considered
`Examiner Signature I /Aarti Bhatia Berdichevsky/
`05/07/2014
`"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ABB/
`
`Novartis Exhibit 2055.008
`Regeneron v. Novartis, IPR2020-01317
`
`

`

`Receipt date: 10/28/2013
`
`13750352 - GAU: 3763
`
`Doc code: IDS
`PT01ss,osa (01-10)
`Approved for use through 0713112012 0MB 0651-0031
`Doc description: Information Disclosure Statement (IDS) Filed
`U.S. Patent and Trade.mart< Office·. U.S. DEPARTMENT OF COMMERCE
`Under tl1e Pape!WOfk Reducllon Act of 1 \\95, no persons are required to respond to a collect!on of information unless It contains a valid 0MB control number.
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99}
`
`Application Number
`
`13750352
`2013-01-25
`Filing Date
`First Named Inventor i Juergen Sigg
`3763
`Art Unit
`!N. D.Shah
`Examiner Name
`Attorney Docket Number
`PAT055157-US-NP
`
`U.S.PATENTS
`
`Examiner Cite
`Initial ..
`No
`
`Patent Number
`
`Kind
`Code 1
`
`Issue Date
`
`Name of Patentee or Applicant Pages.Columns.Lines where
`Relevant Passages or Relevant
`of cited Document
`Figures Appear
`-----
`
`----
`
`1
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`U.S.PATENT APPLICATION PUBLICATIONS
`
`Examiner
`Initial*
`
`Cite No
`
`Publication
`Number
`
`Kind Publication
`Code1 Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages, Columns, Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`1
`
`If you wish to add additional U.S. Published Application citation information please click the Add button.
`FOREIGN PATENT DOCUMENTS
`
`Examiner Cite Foreign Document
`No Number:;
`Initial*
`
`Country
`Code2i
`
`Kind Publication
`Code4 Date
`
`Name of Patentee or
`Applicant of cited
`Document
`
`Pages,Columns,Lines
`where Relevant
`Passages or Relevant
`Figures Appear
`
`TS
`
`1
`
`200224"1264
`
`.JP
`
`A2
`
`2002-08-28
`
`HITOMI KOJI
`
`Abstract
`
`2
`
`0264273
`
`3
`
`0879611
`
`EP
`
`EP
`
`A2
`
`1988-04-20 OKUDA TAMOTSU
`
`eq SHO63-97173
`
`A2
`
`1998-11-25
`
`SUDO MASAMICHI
`
`eq HEI 10-314305
`
`□
`
`□
`
`□
`
`EFSWeb2.1.17
`
`Novartis Exhibit 2055.009
`Regeneron v. Novartis, IPR2020-01317
`
`

`

`Receipt date: 10/28/2013
`
`13750352 - GAU: 3763
`
`Application Number
`
`Filing Date
`First Named Inventor
`
`13750352
`
`2013--01-25
`
`/ Juergen Sigg
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Art Unit
`
`••••••••••••••H
`
`3763
`IN. D. Shah
`Examiner Name
`Attorney Docket Number
`
`PAT055157-US-NP
`
`If you wish to add additionai Foreign Patent Document citation information please click the Add button
`__ ,, _____
`NON-PATENT LITERATURE DOCUMENTS
`
`Examiner Cite
`Initials" No
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`publisher, city and/or country where published.
`
`T5
`
`1
`
`D
`
`lfyou wish to add additional non-patent literature document citation information please click the Add button
`EXAMINER SIGNATURE
`
`Examiner Signature ! /Aarti Bhatia Berdichevsky/
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
`
`I Date Considered I os10112014
`
`., See Kind Codes of USPTO Patent Documents at www.USPTO.GOY or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO
`Standard ST. 3). ' For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`
`• Kind of document by the appropriate symbols as indicated pn the document under WIPO Standard ST_ 16 if possible s Applicant ,s to place a Check mark here i
`
`English language translation is attached.
`
`EfS Web 2.1.17
`
`-••·
`
`'•····
`
`-•-•-•
`
`·•-•·•·•·•·•
`
`a-••
`
`, ...
`
`·•·C
`
`.....
`
`11!11!1·•-•·•·•
`.....
`
`...
`
`... , ..
`
`.,.,:
`
`•·•·•·••·•·••-•·•·•··
`
`----.-. .-.....
`... .... ....
`
`I "' Ill
`
`Novartis Exhibit 2055.010
`Regeneron v. Novartis, IPR2020-01317
`
`